### Bile salts of the coelacanth, Latimeria chalumnae<sup>1</sup>

Kenji Kihira,<sup>2,</sup>\* Yoshio Akashi,\*\* Syoji Kuroki,\*\* Jiro Yanagisawa,\*\* Fumio Nakayama,\*\* and Takahiko Hoshita\*

Institute of Pharmaceutical Sciences, Hiroshima University School of Medicine, Kasumi 1-2-3, Minami-Ku, Hiroshima, 734, Japan\* and First Department of Surgery, Kyusyu University School of Medicine, Maedashi 3-1-1, Higashi-Ku, Fukuoka, 812, Japan\*\*

Abstract Bile salts of the coelacanth, Latimeria chalumnae, Smith, have been analyzed and shown to have three bile alcohols, latimerol,  $5\alpha$ -cyprinol, and  $5\alpha$ -cholestane- $3\beta$ ,  $7\alpha$ ,- $12\alpha$ , 25, 26-pentol, two C<sub>24</sub> bile acids, chenodeoxycholic acid and cholic acid, one C<sub>26</sub> bile acid, probably  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy-27-nor-5 $\alpha$ -cholestan-26-oic acid, and two C<sub>27</sub> bile acids,  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid and  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ trihydroxy-5 $\alpha$ -cholestan-26-oic acid as determined by gasliquid chromatography and gas-liquid chromatography-mass spectrometry.-Kihira, K., Y. Akashi, S. Kuroki, J. Yanagisawa, F. Nakayama, and T. Hoshita. Bile salts of the coelacanth, Latimeria chalumnae. J. Lipid Res. 1984. 25: 1330-1336.

Supplementary key words bile alcohols • sulfate esters • gas-liquid chromatography-mass spectrometry

Bile salts of the coelacanth, Latimeria chalumnae, the most primitive of the living bony fishes, have been shown to contain the 26-sulfate of latimerol,  $5\alpha$ -cholestane-3 $\beta$ ,7 $\alpha$ ,12 $\alpha$ ,26,27-pentol, as the principal bile salt (1, 2). Biochemically latimerol is the most primitive of naturally occurring bile alcohols, having the complete  $5\alpha$ -cholestane carbon skeleton with the  $\beta$ -orientated 3hydroxyl group as in cholesterol. The coelacanth also contains sulfate esters of  $5\alpha$ -cyprinol,  $5\alpha$ -cholestane- $3\alpha,7\alpha,12\alpha,26,27$ -pentol, and  $5\alpha$ -bufol (3),  $5\alpha$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 25, 26-pentol, and very small amounts of conjugated bile acids. However, the chemical structures of the bile acids have not yet been elucidated.

This report describes the results of an examination of the biliary bile acids and bile alcohols of the coelacanth by means of glass capillary gas-liquid chromatography and gas-liquid chromatography-mass spectrometry.

### MATERIALS AND METHODS

#### General

Melting points, infrared (IR) spectra, thin-layer chromatography (TLC), and proton nuclear magnetic resonance (PMR) spectra were as described previously (4).

Gas-liquid chromatography (GLC) was performed on

a Shimadzu model GC-6A gas chromatograph equipped with a flame ionization detector and Van den Berg's solventless injector. The column used was WCOT, 25  $m \times 0.35$  mm i.d., coated with SE-30 (LKB-Produkter) and the column temperature was 270°C. Bile alcohols were analyzed as their trimethylsilyl (TMS) derivatives and the retention times are given relative to the TMS ether of methyl cholate. Bile acids were analyzed as their methyl ester-dimethylethylsilyl (DMES) ether derivatives and the retention times are given relative to the DMES ether derivative of methyl cholate. Quantitation was accomplished by comparing GLC peak areas of the biological samples with that of external standard, the TMS or DMES ether of methyl cholate.

Gas-liquid chromatography-mass spectrometry (GLC-MS) was carried out on a Shimadzu model GCMS-9000 gas chromatograph-mass spectrometer equipped with a data processing system (Shimadzu GCMSPAC-90) and Van den Berg's solventless injector. The following operating conditions were employed: column: SE-30 (25 m  $\times$  0.35 mm i.d.); column oven temperature: 270°C; ionization energy: 22.5 eV; acceleration voltage: 3.5 KV; trap current: 100  $\mu$ A.

### **Reference** compounds

Cholic acid and chenodeoxycholic acid were commercial products.  $5\alpha$ -cyprinol (5),  $5\alpha$ -bufol (6),  $5\beta$ -bufol  $(5\beta$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 25, 26-pentol) (7),  $5\alpha$ -cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 26-tetrol (8),  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ cholestan-26-oic acid (9), and  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\beta$ cholestan-26-oic acid (10) were isolated from natural sources according to the procedures previously reported.

**OURNAL OF LIPID RESEARCH** 

Abbreviations: IR, infrared; TLC, thin-layer chromatography; GLC, gas-liquid chromatography; RRT, relative retention time; GLC-MS, gas-liquid chromatography-mass spectrometry; PMR, proton magnetic resonance; TMS, trimethylsilyl; DMES, dimethylethylsilyl.

This paper is part XXIX of a series entitled "Comparative biochemical studies of bile acids and bile alcohols." Part XXVIII: Kihira, K., A. Kubota, and T. Hoshita. J. Lipid Res. 1984. 25: 871-875. <sup>2</sup> To whom correspondence should be addressed.

 $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -Trihydroxy-27-nor- $5\beta$ -cholestan-26-oic acid was prepared according to the method previously reported (11).

### Synthesis of $5\alpha$ -cholestane- $3\beta$ , $7\alpha$ , $12\alpha$ , 25, 26-pentol

 $5\alpha$ -Cholestane- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ , 26-tetrol prepared from  $5\alpha$ cyprinol sulfate (8) was converted into  $5\alpha$ -cholest-25-ene- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -triol as described previously (6). The fully acetylated derivative of  $5\alpha$ -cholest-25-ene- $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -triol (580 mg) was partially hydrolyzed with 0.36 N methanolic HCl to yield  $7\alpha$ ,  $12\alpha$ -diacetoxy- $5\alpha$ cholest-25-en-3 $\alpha$ -ol, which was then oxidized with CrO<sub>3</sub> to give  $7\alpha$ ,  $12\alpha$ -diacetoxy- $5\alpha$ -cholest-25-en-3-one. The diacetoxycholestenone was reduced with NaBH4 and hydrolyzed with 5% methanolic KOH. The major product was purified on a reversed-phase column (Lober, Lichroprep, RP-8, 2.5 cm × 31 cm, Merck) using 87.5% aqueous methanol as an eluting solvent. Recrystallization from methanol-water gave crystals (78 mg) of  $5\alpha$ -cholest-25-ene- $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -triol with mp of 200.5-201.5°C; TLC (RP-18 plate): R<sub>f</sub> 0.55 (solvent system: methanol-water 10:1); IR: 3350 (hydroxyl), 1030, 720 (characteristic bands for  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestane nucleus) (2), 1636, 883 (end methylene); PMR (pyridine-d<sub>5</sub>): 0.80 (s, 3H, 18-H<sub>3</sub>), 0.90 (3H, s, 19-H<sub>3</sub>), 1.20 (d, J = 6 Hz, 3H, 21-H<sub>3</sub>), 1.70 (s, 3H, 27-H<sub>3</sub>), 3.80 (m, 1H,  $3\alpha$ -H), 4.07 (m, 1H,  $7\beta$ -H), 4.22 (m, 1H,  $12\beta$ -H), 4.79 (s, 2H, 26-H<sub>2</sub>).

 $5\alpha$ -Cholest-25-ene- $3\beta$ , $7\alpha$ , $12\alpha$ -triol (77 mg) was oxidized with OsO<sub>4</sub> according to the procedure described previously (6). Recrystallization from methanol-water gave crystals (60 mg) of  $5\alpha$ -cholestane- $3\beta$ , $7\alpha$ , $12\alpha$ ,25,26-pentol with mp 253°C; IR: 3350 (hydroxyl), 1030, 720; PMR (pyridine-d<sub>5</sub>): 0.80 (s, 3H, 18-H<sub>3</sub>), 0.90 (s, 3H, 19-H<sub>3</sub>), 1.23 (d, J = 6 Hz, 3H, 21-H<sub>3</sub>), 1.46 (s, 3H, 27-H<sub>3</sub>), 3.80 (m, 1H,  $3\alpha$ -H), 3.83 (s, 2H, 26-H<sub>2</sub>), 4.07 (m, 1H,  $7\beta$ -H), 4.23 (m, IH,  $12\beta$ -H).

# Synthesis of $3\beta$ , $7\alpha$ , $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid

The fully acetylated derivative of  $5\alpha$ -cholestane- $3\alpha$ , $7\alpha$ , $12\alpha$ ,26-tetrol (400 mg) was partially hydrolyzed with 0.36 N methanolic HCl. The product was purified on a silica gel column chromatograph using benzeneethyl acetate 3:7 as the eluting solvent to yield a low melting solid (370 mg) of  $7\alpha$ , $12\alpha$ -diacetoxy- $5\alpha$ -cholestane- $3\alpha$ ,26-diol: TLC (silica gel G):  $R_f$  0.59 (solvent system: benzene-ethyl acetate 3:7); IR: 3400 (hydroxyl), 1730 (acetate); PMR (CDCl<sub>3</sub>): 0.71 (3H, s, 19-H<sub>3</sub>), 0.76 (3H, s, 18-H<sub>3</sub>), 0.80 (3H, d, J = 6 Hz, 21-H<sub>3</sub>), 0.90 (3H, d, J = 6 Hz, 27-H<sub>3</sub>), 2.07 (6H, s, CH<sub>3</sub>CO-x2), 3.20 (2H, m, 26-H<sub>2</sub>OH), 4.30 (1H, m,  $3\beta$ -H), 4.93 (1H, m,  $7\beta$ -H), 5.07 (1H, m,  $12\beta$ -H).

 $7\alpha$ ,  $12\alpha$ -Diacetoxy- $5\alpha$ -cholestane- $3\alpha$ , 26-diol (200 mg)

was oxidized with Jones reagent. The product was purified on a reversed-phase column (RP-8, 2.5 cm  $\times$  31 cm, Merck) using 75% aqueous methanol as an eluting solvent to yield a low melting solid (72 mg) of 3-oxo-7 $\alpha$ ,12 $\alpha$ -diacetoxy-5 $\alpha$ -cholestan-26-oic acid: TLC (silica gel G):  $R_f$  0.45 (solvent system: benzene-ethyl acetate 3:7); IR: 1730 (carbonyl, acetate and carboxyl); PMR (CDCl<sub>3</sub>): 0.75 (3H, s, 18-H<sub>3</sub>), 0.80 (3H, d, J = 6 Hz, 21-H<sub>3</sub>), 1.05 (3H, s, 19-H<sub>3</sub>), 1.23 (3H, d, J = 6 Hz, 27-H<sub>3</sub>), 2.07 (6H, s, CH<sub>3</sub>-CO-x2), 4.98 (1H, m, 7 $\beta$ -H), 5.09 (1H, m, 12 $\beta$ -H).

Fifty mg of 3-0x0-7 $\alpha$ , 12 $\alpha$ -diacetoxy-5 $\alpha$ -cholestan-26oic acid in methanol was treated with NaBH<sub>4</sub>. The reaction mixture was then hydrolyzed with 10% methanolic KOH. Repeated recrystallization from methanol gave colorless needles of  $3\beta$ ,  $7\alpha$ , 12 $\alpha$ -trihydroxy-5 $\alpha$ -cholestan-26-oic acid with mp 228-229°C; TLC (silica gel G):  $R_f$  0.38 (solvent system: isooctane-ethyl acetateacetic acid 5:5:1); IR: 3400 (hydroxyl), 1730 (carboxyl), 1030, 720; PMR (pyridine-d<sub>5</sub>): 0.80 (3H, s, 18-H<sub>3</sub>), 0.90 (3H, s, 19-H<sub>3</sub>), 1.23 (3H, d, J = 6 Hz, 21-H<sub>3</sub>), 1.32 (3H, d, J = 6 Hz, 27-H<sub>3</sub>), 3.80 (1H, m,  $3\alpha$ -H), 4.09 (1H, m,  $7\beta$ -H), 4.23 (1H, m,  $12\beta$ -H).

## Analysis of bile alcohols and bile acids in the bile of the coelacanth

A frozen sample (1 ml) of gallbladder bile of the coelacanth was supplied by Japanese Scientific Investigation Party on Coelacanth, Committee for Anatomy and Analysis. The bile sample was extracted with 10 volumes of ethanol at room temperature. The ethanolic extract was evaporated under a reduced pressure to leave crude bile salts as a deep brown solid (about 60 mg). Solvolysis of one-third of the crude bile salts was carried out according to the procedure described previously (12) and extraction of the solvolyzed bile salts with ethyl acetate-n-butanol 1:1 gave a mixture (11 mg) of desulfated bile alcohols. Two mg of the bile alcohol mixture was converted to TMS ether derivatives and analyzed by GLC and GLC-MS. The remaining part (9 mg) of the bile alcohol mixture was crystallized from acetone to give crystals of the principal bile alcohol of the coelacanth, latimerol, with mp 235-236°C, [reported 236°C (2)].

The aqueous phase left from the n-butanol-ethyl acetate extraction was percolated through a Sep-Pak  $C_{18}$  cartridge (Waters Associates) and after washing with 15 ml of water the cartridge was eluted with 10 ml of methanol. After removal of the solvent, the residue containing conjugated bile acids was hydrolyzed with 2.5 N KOH solution at 130°C for 3 hr. After dilution with water and acidification with diluted HCl, the hydrolyzate was extracted with ether. After washing with

water, the extract was evaporated to dryness to give a residue (less than 1 mg) containing deconjugated bile acids, which was converted to methyl ester-DMES ether derivatives and analyzed by GLC and GLC-MS.

### RESULTS

Preliminary TLC analysis revealed that the coelacanth bile contained bile alcohol sulfates as the major constituents and lesser amounts of taurine-conjugated bile acids. Solvolysis of the crude bile salts gave a mixture of desulfated bile alcohols. The principle bile alcohol of the coelacanth was easily isolated from the bile alcohol mixture by repeated recrystallization, and identified as latimerol by comparison of its melting point and IR spectrum with the reported data. As shown in **Fig. 1**, GLC analysis revealed that the bile alcohol mixture contained two minor bile alcohols corresponding to

SBMB

**OURNAL OF LIPID RESEARCH** 



Fig. 1. Gas chromatogram of TMS ether derivative of the bile alcohol mixture of the coelacanth. The peak number corresponds to the mass spectrum number in Fig. 2. Peak 1:  $5\alpha$ -cholestane- $3\beta$ , $7\alpha$ ,  $12\alpha$ , 25, 26-pentol; peak 2:  $5\alpha$ -cyprinol; peak 3: latimerol.

GLC peaks 1 (2% of the total bile alcohols) and 2 (5%) at RRTs 2.54 and 2.63, respectively, in addition to the major bile alcohol, latimerol, which was chromatographed as the peak 3 (93%) at RRT of 2.81. The concentration of the bile alcohols estimated by GLC was 20.0 mg/ml. The mass spectra 1-3 of the TMS ether derivatives of the bile alcohols corresponding to GLC peaks 1-3, respectively, are shown in **Fig. 2**.

One of the minor bile alcohols, which was chromatographed as the peak 2 on GLC, was identified as  $5\alpha$ cyprinol. The mass spectrum and the RRT of its TMS ether derivative were completely identical with those of the TMS ether derivative of authentic  $5\alpha$ -cyprinol.

The mass spectrum 1 was almost identical with that obtained from the TMS ether derivative of authentic  $5\alpha$ -bufol, suggesting that the bile alcohol chromatographed as the peak 1 on GLC is a stereoisomer of  $5\alpha$ bufol. In both spectra, a series of fragment ions at m/z797, 707, 617, 527, and 437 was seen. This series results from the scission of the bond between C-25 and C-26 followed by the subsequent loss of TMS ether groups (13). The peak at m/z 219 is a side chain fragment resulting from the scission of the bond between C-24 and C-25. The ions at m/z 343 and 253 represent loss of the entire side chain plus two and three nuclear TMS ether groups, respectively. The intensity of the ion at m/z 343 is greater than that of the ion at m/z253 in both spectra, indicating that the bile alcohol corresponding to the peak 1 as well as  $5\alpha$ -bufol is a  $5\alpha$ bile alcohol (14). On the GLC, the ratio of the RRTs between the peak 1 (2.54) and  $5\alpha$ -bufol (2.38) was equal to that of the RRTs of latimerol (peak 3) and  $5\alpha$ cyprinol (peak 2). These results suggest that the peak 1 is of the  $3\beta$ -epimer of  $5\alpha$ -bufol. In order to confirm this structural assignment, a partial synthesis of 3-epi-5 $\alpha$ bufol, 5 $\alpha$ -cholestane-3 $\beta$ , 7 $\alpha$ , 12 $\alpha$ , 25, 26-pentol, was performed. The synthetic 3-epi-5 $\alpha$ -bufol (probably a mixture of C-25 isomers, which could not be resolved on the GLC system employed in this study) showed the identical behavior on GLC and mass spectrum to the natural bile alcohol corresponding to the peak 1 on GLC.

Alkaline hydrolysis of the bile salts of the coelacanth afforded a mixture of deconjugated bile acids, of which the GLC chromatogram as the methyl ester-DMES ether derivative is shown in **Fig. 3**. There were at least five bile acid peaks 4-8 at RRTs of 0.76 (8% of the total bile acids), 1.00 (32%), 1.55 (3%), 1.59 (5%), and 1.64 (51%), respectively. The concentration of the total bile acid estimated by GLC was 0.6 mg/ml of bile. The mass spectra 4-8 corresponding to the peaks 4-8, respectively, are shown in **Fig. 4**.

The bile acids corresponding to the peaks 4, 5, and 7 were identified with certainty as chenodeoxycholic acid, cholic acid, and  $3\alpha$ , $7\alpha$ , $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-





Fig. 2. Mass spectra of the coelecanth bile alconois (as 1 MS ether derivatives). The mass spectrum number corresponds to the peak number in Fig. 1. 1:  $5\alpha$ -Cholestane- $3\beta$ , $7\alpha$ , $12\alpha$ ,25,26-pentol; 2:  $5\alpha$ -cyprinol; 3: latimerol.

26-oic acid, respectively, by comparison of their mass spectra and chromatographic properties with those of authentic compounds.

The mass spectrum 8, the major bile acid corresponding to the peak 8 on GLC, was almost identical with the mass spectrum 7 of  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid. In both spectra, the base peak was seen at 693 which is formed by the loss of ethyl group from the molecular ion. There was a series of fragment ions at m/z 618, 514, and 411, which is formed by the successive loss of the DMES ether groups from the molecular ion. The ions at m/z 357 and 253 represent loss of side chain plus two and three nuclear DMES ether groups, respectively. The ion at m/z 303 is formed by the cleavage of the 6,7- and 9,10-bonds plus loss of two DMES ether groups at C-7 and C-12. These data suggest that the difference between the two is a stereochemical one, most likely at C-3 as in relation between latimerol and  $5\alpha$ -cyprinol. To confirm this structural assignment, a partial synthesis of  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ trihydroxy- $5\alpha$ -cholestan-26-oic acid was performed. The synthetic  $3\beta$ -hydroxylated bile acid (probably a mixture

of C-25 isomers, which could not be resolved on the GLC system employed in this study) was completely identical, as judged by GLC and GLC-MS, with the natural bile acid corresponding to the peak 8 on GLC.

The mass spectrum 6 showed a pattern comparable to the mass spectrum 8 of  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ cholestan-26-oic acid but with 14 mass units less with respect to the fragments containing the side chain. The mass spectrum 6 showed a weak molecular ion at m/z 708 and the base peak at m/z 679 which is formed by the loss of ethyl group from the molecular ion. The series of fragment ions at m/z 604, 500, and 397 results from the successive loss of one, two, and three DMES ether groups from the molecular ion. The fragment at m/z 575 is formed by the loss of a DMES ether group from the m/z 679 fragment. The fragments at m/z469 and 365 result from the loss of CH<sub>3</sub>O- (31 mass units) moiety from the m/z 500 and 397 fragments, respectively. The fragment ion formed by the cleavage of the 6,7- and 9,10-bonds plus loss of two DMES ether groups was seen at m/z 289. In the mass spectrum 6 as well as in the mass spectrum 8, the intensity of the ion



Fig. 3. Gas chromatogram of methyl ester-DMES ether derivative of the bile acid mixture of the coelacanth. The peak number corresponds to the mass spectrum number in Fig. 4. Peak 4: chenodeoxycholic acid; peak 5: cholic acid; peak 6:  $3\beta$ , $7\alpha$ , $12\alpha$ -trihydroxy-27-nor- $5\alpha$ -cholestan-26-oic acid; peak 7:  $3\alpha$ , $7\alpha$ , $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; peak 8:  $3\beta$ , $7\alpha$ , $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid;

at m/z 357 (M-side chain-2 × DMES-OH) was greater than that of the ion at m/z 253 (M-side chain-3 × DMES-OH) suggesting that the bile acid corresponding is a 5 $\alpha$ -bile acid (14). These spectral data suggest that the peak 6 is of a trihydroxy-5 $\alpha$ -C<sub>26</sub> bile acid. On GLC, the RRT ratio of the peak 6 and the methyl ester-DMES ether derivative of  $3\alpha$ , $7\alpha$ ,  $12\alpha$ -trihydroxy-27-nor-5 $\beta$ -cholestan-26-oic acid (RRT = 1.56) was almost equal to that between the peak 8 of  $3\beta$ , $7\alpha$ ,  $12\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid and  $3\alpha$ , $7\alpha$ ,  $12\alpha$ -trihydroxy-5 $\beta$ -cholestan-26-oic acid (RRT = 1.63). These results indicate, but do not prove, that the peak 6 is probably of  $3\beta$ , $7\alpha$ ,  $12\alpha$ -trihydroxy-27-nor-5 $\alpha$ -cholestan-26-oic acid.

### DISCUSSION

The present study has confirmed the results from previous investigations (1, 2) that showed that the coelacanth bile contains latimerol and  $5\alpha$ -cyprinol as the major and the minor bile alcohols, respectively. Biosynthesis of  $5\alpha$ -cyprinol, the  $3\alpha$ -epimer of latimerol, has been studied by Hoshita (15, 16) using carp whose major bile alcohol is this  $3\alpha$ -hydroxylated  $5\alpha$ -bile alcohol.

1334 Journal of Lipid Research Volume 25, 1984

The biosynthetic pathway of  $5\alpha$ -cyprinol might involve the following intermediates: cholesterol  $\rightarrow$  cholest-5-ene- $3\beta$ ,  $7\alpha$ -diol  $\rightarrow$   $7\alpha$ -hydroxycholest-4-en-3-one  $\rightarrow$   $7\alpha$ ,  $12\alpha$ dihydroxycholest-4-en-3-one $\rightarrow$ 7 $\alpha$ ,12 $\alpha$ -dihydroxy-5 $\alpha$ cholestan-3-one $\rightarrow$ 5 $\alpha$ -cholestane-3 $\alpha$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol $\rightarrow$  $5\alpha$ -cyprinol. Although there is no experimental evidence, the coexistence of  $5\alpha$ -cyprinol and its  $3\beta$ -isomer, latimerol, in Latimeria bile suggests that latimerol probably arises from cholesterol by the same route as in the biosynthesis of  $5\alpha$ -cyprinol, except for the stereochemistry of the reduction of the 3-oxo group in  $7\alpha$ ,  $12\alpha$ dihydroxy- $5\alpha$ -cholestan-3-one, rather than by the route which maintains the  $3\beta$ -hydroxyl group of cholesterol throughout. In the Latimeria liver most of the 3-oxo intermediate would be converted into  $5\alpha$ -cholestane- $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -triol which is then hydroxylated successively at C-26 and C-27 to form latimerol.

Amos et al. (3) have reported the presence of small amounts of  $5\alpha$ -bufol in the coelacanth bile in addition to latimerol and  $5\alpha$ -cyprinol though experimental details had not been given. However, we were unable to find this  $3\alpha$ -hydroxylated bile alcohol. Instead of  $5\alpha$ -bufol, we found a new bile alcohol as the third biliary bile alcohol of the *Latimeria* and elucidated its structure as the  $3\beta$ -epimer of  $5\alpha$ -bufol, although the configuration



Fig. 4. Mass spectra of the coelacanth bile acids (as methyl ester-DMES ether derivatives). The mass spectrum number corresponds to the peak number in Fig. 3. 4: Chenodeoxycholic acid; 5: cholic acid; 6:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy-27-nor- $5\alpha$ -cholestan-26-oic acid; 7:  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 7:  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid; 8:  $3\beta$ ,  $3\alpha$ ,  $3\beta$ 

JOURNAL OF LIPID RESEARCH

at C-25 is not clarified, by the direct comparison with a synthesized sample. It seems more likely that the coelacanth bile contains 3-epi-5 $\alpha$ -bufol rather than 5 $\alpha$ -bufol in respect to the relative abundance of latimerol and 5 $\alpha$ -cyprinol in the bile of this species, and that 3-epi-5 $\alpha$ -bufol may possibly represent a subproduct which is formed from 5 $\alpha$ -cholestane-3 $\beta$ ,7 $\alpha$ ,12 $\alpha$ ,26-tetrol, the direct precursor of latimerol, by 25-hydroxylation instead of 27-hydroxylation.

The presence of bile acids in very small amounts in the Latimeria bile has previously been reported by Anderson and Haslewood (1, 2). However, their chemical structures have not yet been elucidated. The present study confirmed the presence (0.6 mg/ml bile) of at least five bile acids in the bile of the coelacanth. Three of them were known bile acids, and by direct comparison with authentic samples they were identified as cholic acid, chenodeoxycholic acid, and  $3\alpha$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid, respectively. The remainder were new bile acids. The major one was assumed to be  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy- $5\alpha$ -cholestan-26-oic acid. Although the configuration at C-25 was not clarified, chemical synthesis permitted the identification of this  $3\beta$ -hydroxylated higher bile acid. The other one was identified tentatively as  $3\beta$ ,  $7\alpha$ ,  $12\alpha$ -trihydroxy-27-nor- $5\alpha$ -cholestan-26-oic acid by comparison of its properties on GLC and mass spectral data with those of comparable compounds.

It is very interesting that the coelacanth bile contains not only the higher bile acids possessing 27 and presumably 26 carbon atoms but also the most common  $C_{24}$ bile acids, cholic acid and chenodeoxycholic acid. Carp and related fishes also contain small amounts of cholic acid in their bile. Hoshita (15, 16) and Kouchi (17, 18) have shown that such fishes could convert labeled cholesterol or cholest-5-ene- $3\beta$ ,  $7\alpha$ -diol into radioactive cholic acid as well as  $5\alpha$ -cyprinol. The presence of cholic acid and chenodeoxycholic acid in the coelacanth bile might indicate that the enzyme system capable of degrading the cholesterol side chain was present even in the most primitive bony fish, the coelacanth, as well as in carp and related fishes. It should, however, be noted that the coelacanth is a carnivorous fish, and taurocholate and taurochenodeoxycholate are the major bile salts in almost all species of marine teleosts. The possibility that the  $5\beta$ -C<sub>24</sub> bile acids found in the Latimeria bile originate from the diet is not fully excluded.

The  $C_{27}$  bile acids found in the coelacanth bile seemed to be endogenous since these higher bile acids have not been detected in any other marine fishes. The *Latimeria*  $C_{27}$  bile acids may possibly represent subproducts that are formed from  $5\alpha$ -cholestane- $3\beta$ , $7\alpha$ ,  $12\alpha$ , 26tetrol and its  $3\alpha$ -epimer, the biosynthetic precursors of the *Latimeria* bile alcohols, by an oxidation of the 26hydroxyl group to a carboxylic group.

Manuscript received 7 March 1984.

1336 Journal of Lipid Research Volume 25, 1984

### REFERENCES

- 1. Haslewood, G. A. D. 1964. Bile salts of a coelacanth, Latimeria chalumnae, Smith. Biochem. J. 93: 22p.
- Anderson, I. G., and G. A. D. Haslewood. 1964. Comparative studies of 'bile salts'. 20. Bile salts of the coelacanth, *Latimeria chalumnae, Smith. Biochem. J.* 93: 34-39.
- Amos, B., I. G. Anderson, G. A. D. Haslewood, and L. Tokes. 1977. Bile salts of the lungfishes *Lepidosiren*, Neoceratodus and Protopterus and those of the coelacanth Latimeria chalumnae, Smith. Biochem. J. 161: 201-204.
- 4. Une, M., F. Nagai, K. Kihira, T. Kuramoto, and T. Hoshita. 1983. Synthesis of four diastereoisomers at carbons 24 and 25 of  $3\alpha$ , $7\alpha$ , $12\alpha$ ,24-tetrahydroxy-5 $\beta$ -cholestan-26-oic acid, intermediates of bile acid biosynthesis. J. Lipid Res. 24: 924-929.
- Hoshita, T., S. Nagayoshi, and T. Kazuno. 1963. Sterobile acids and bile sterols. LIV. Studies on the bile of carp. J. Biochem. (Tokyo) 54: 369-373.
- 6. Hoshita, T., S. Hirofuji, T. Nakagawa, and T. Kazuno. 1967. Stero-bile acids and bile sterols. XCVI. Studies on the bile salts of the newt and synthesis of  $5\alpha$ -cholestane- $3\alpha$ , $7\alpha$ , $12\alpha$ ,25,26-pentol( $5\alpha$ -bufol). J. Biochem. (Tokyo) 62: 62-66.
- 7. Okuda, K., T. Hoshita, and T. Kazuno. 1962. Stero-bile acids and bile sterols. XLI. Isolation of a new bile sterol,  $3\alpha$ , $7\alpha$ , $12\alpha$ ,25,26-pentahydroxycoprostane from toad bile. *J. Biochem. (Tokyo)* **51:** 48–55.
- Hoshita, T. 1962. Stero-bile acids and bile sterols. XLVI. Isolation of a new bile sterol, 3α,7α,12α-trihydroxy-26,27epoxycholestane from carp bile. J. Biochem. (Tokyo) 52: 125-130.
- Okuda, K., M. G. Horning, and E. C. Horning. 1972. Isolation of a new bile acid, 3α,7α,12α-trihydroxy-5αcholestan-26-oic acid, from lizard bile. J. Biochem. (Tokyo) 71: 885-890.
- Komatsubara, T. 1954. The synthesis of stero-bile acid. VIII. On the bile acid of *Rana nigromaculata nigromaculata*. Proc. Japan Acad. 30: 614-617.
- Kazuno, T., A. Mori, and T. Goto. 1955. The synthesis of stero-bile acid. XII. The partial synthesis of bisnorsterocholic acid by Kolbe electrolytic reaction. J. Biochem. (Tokyo) 42: 77-80.
- 12. Anderson, I. G., G. A. D. Haslewood, R. S. Oldham, B. Amos, and L. Tokes. 1974. A more detailed study of the bile salt evolution, including techniques for small-scale identification and their application to amphibian biles. *Biochem. J.* 141: 485-494.
- 13. Kihira, K., M. Yasuhara, T. Kuramoto, and T. Hoshita. 1977. New bile alcohols,  $5\alpha$  and  $5\beta$ -dermophols from amphibians. *Tetrahedron Lett.* 687–690.
- Une, M., T. Kuramoto, and T. Hoshita. 1983. The minor bile acids of the toad, Bufo vulgaris formosus. J. Lipid Res. 24: 1468-1474.
- 15. Hoshita, T. 1964. Stero-bile acids and bile sterols. LXII. Formation of  $5\alpha$ -cyprinol from cholesterol in carp. *Steroids*. **3:** 523-529.
- 16. Hoshita, T. 1967. Stero-bile acids and bile alcohols. LXXXVIII. Formation of bile acids and alcohols from cholestanol and  $7\alpha$ -hydroxycholesterol in the carp. J. Biochem. (Tokyo) **61:** 440-449.
- Kouchi, M. 1963. Stero-bile acids and bile sterols. LIX. Formation of bile acids from cholesterol in eel. *Hiroshima* J. Med. Sci. 12: 163-170.
- Kouchi, M. 1965. Stero-bile acids and bile alcohols. LXXX. Metabolism of cholesterol in *Carrassius carrassius*. *Hiroshima* J. Med. Sci. 14: 195-202.